**Supplementary Data**

Additional details for TEAEs and TRAEs for all doses in the escalation cohort

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table S1.** Summary of TEAEs of any grade occurring in ≥20% of patients, and telisotuzumab grade ≥3 TRAEs | | | | | | | | |
|  | **Adverse events of any grade in ≥20% of patients**  **n (%)** | | | | **Grade ≥3 AEs related to telisotuzumab**  **n (%)** | | | |
|  | **5 mg/kg**  **(n=3)** | **10 mg/kg**  **(n=3)** | **15 mg/kg**  **(n=3)** | **25 mg/kg**  **(n=6)** | **5 mg/kg**  **(n=3)** | **10 mg/kg**  **(n=3)** | **15 mg/kg**  **(n=3)** | **25 mg/kg**  **(n=6)** |
| **Any AE** | 3 (100) | 3 (100) | 2 (66.7) | 6 (100) | 0 | 2 (66.7) | 0 | 1 (16.7) |
| Peripheral edema | 1 (33.3) | 1 (33.3) | 2 (66.7) | 3 (50.0) | 0 | 0 | 0 | 0 |
| Hypoalbuminemia | 1 (33.3) | 1 (33.3) | 1 (33.3) | 3 (50.0) | 0 | 1 (33.3) | 0 | 1 (16.7) |
| Constipation | 2 (66.7) | 1 (33.3) | 0 | 2 (33.3) | 0 | 0 | 0 | 0 |
| Hypokalemia | 2 (66.7) | 1 (33.3) | 0 | 2 (33.3) | 0 | 0 | 0 | 0 |
| Malignant neoplasm progression | 0 | 2 (66.7) | 0 | 3 (50.0) | 0 | 0 | 0 | 0 |
| Nausea | 2 (66.7) | 2 (66.7) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Dehydration | 1 (33.3) | 2 (66.7) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Fatigue | 1 (33.3) | 1 (33.3) | 1 (33.3) | 1 (16.7) | 0 | 0 | 0 | 0 |
| Vomiting | 0 | 2 (66.7) | 0 | 2 (33.3) | 0 | 0 | 0 | 0 |
| Ascites | 1 (33.3) | 2 (66.7) | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypophosphatemia | 2 (66.7) | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Hypotension | 0 | 1 (33.3) | 0 | 2 (33.3) | 0 | 0 | 0 | 0 |
| Pain in extremity | 1 (33.3) | 1 (33.3) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Urinary tract infection | 1 (33.3) | 1 (33.3) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Anemia | 1 (33.3) | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Arthralgia | 1 (33.3) | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Back pain | 1 (33.3) | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Increased blood ALP | 1 (33.3) | 1 (33.3) | 0 | 0 | 0 | 1 (33.3) | 0 | 0 |
| Increased blood creatinine | 0 | 1 (33.3) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Decreased appetite | 1 (33.3) | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Deep vein thrombosis | 0 | 0 | 0 | 2 (33.3) | 0 | 0 | 0 | 0 |
| Dyspnea | 2 (66.7) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyponatremia | 1 (33.3) | 1 (33.3) | 0 | 0 | 0 | 1 (33.3) | 0 | 0 |
| Leukocytosis | 0 | 1 (33.3) | 0 | 1 (16.7) | 0 | 0 | 0 | 1 (16.7) |
| Decreased lymphocyte count | 0 | 2 (66.7) | 0 | 0 | 0 | 1 (33.3) | 0 | 0 |
| Myalgia | 1 (33.3) | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Pollakiuria | 0 | 1 (33.3) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Pruritus | 0 | 1 (33.3) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Tachycardia | 0 | 1 (33.3) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Vertigo | 0 | 1 (33.3) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Abdominal distension | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Abdominal pain | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Abdominal wall abscess | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acute kidney injury | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Increased ALT | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Alopecia | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Anxiety | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Increased AST | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Increased blood urea | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Diarrhea | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Failure to thrive | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal gastrointestinal sounds | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Groin pain | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperhydrosis | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypertension | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ileus | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Influenza-like illness | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Insomnia | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Jaundice | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Ligament sprain | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Microcytic anemia | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Muscle spasms | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Muscular weakness | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Musculoskeletal chest pain | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nail discoloration | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Noncardiac chest pain | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Orthostatic hypotension | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Osteopenia | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Overdose | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pneumonia | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Proteinuria | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pyrexia | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Scrotal swelling | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Seborrhea | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Sinusitis | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stomatitis | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Decreased thyroxine | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Ulcerative keratitis | 0 | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Upper respiratory tract infection | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urobilinogen in urine | 0 | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 |
| Wheezing | 1 (33.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Decreased protein total | 0 | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 1 (16.7) |
| AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TEAE, treatment-emergent AE; TRAE, treatment-related AE. | | | | | | | | |